Oculis, a clinical-stage biotechnology company developing next-generation topical treatments for acute and chronic back- and front-of-the-eye diseases, announced yesterday that it has named Anthony Rosenberg as its new non-executive chairman and David A Weber, PhD as its new non-executive director.
Rosenberg has more than 35 years experience in the pharmaceutical sector. He is a managing director at MPM Capital and earlier served as global head, M&A and Licensing (Corporate) for Novartis, based in Basel, Switzerland. He is a board member at MPM portfolio companies Radius, Cullinan and TriNetX. In addition, he is also an independent board member at argenx BV.
Dr Weber has worked in the healthcare industry for more than 25 years, including ten years in ophthalmic drug development. He is presently president, CEO and director of Otonomy Inc (NASDAQ :OTIC ). Prior to Otonomy, he was CEO at MacuSight Inc. Dr Weber also held various management positions at Oral-B Laboratories and Procter & Gamble.
Bioforum, The Data Masters names new President
VolitionRx names new Chief Medical Officer
Quotient Sciences announces new appointments
Syndax Pharmaceuticals names new chief commercial officer
Everest Medicines names new chief medical officer and chief product officer
D3 Bio names new independent board member
Rigel Pharmaceuticals names new executive vice president and chief medical officer
Telix Pharmaceuticals names new group chief operating officer